Stock Market News1 month MRK’s Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals Zacks
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.
XMerck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.
X